Researchers from the University Medical Center Rostock and Viennese biotechnology company Themis have succeeded in developing a vaccine against the dangerous chikungunya virus. Since there is no specific treatment for the Chikungunya fever, vaccination is of particular importance, reported the head of the Department of Tropical Medicine and Infectiology of Unimedizin Rostock, Emil Reisinger, in a study that was published on Tuesday in the journal "The Lancet" , Chikungunya fever is a viral infection transmitted by Aedes mosquitoes, which has become very widespread in recent years. It occurs mainly in tropical and subtropical regions. "In the treatment groups, after two injections, antibodies were detected in 86.4 to 100 percent of the vaccinated." The vaccine is based on a measles virus.
Editor's note: This message from the German Press Agency (dpa) is part of an automated offer that is played on our website. Neither the content nor the spelling were checked by the t-online.de editorial staff. The dpa works but strictly according to journalistic standards. If you still discover errors, we look forward to hearing from you. Thank you very much! ,